Sector: Healthcare

Small Cap

QLine Biotech Share Price

QLINE

₹517

-7.05(-1.35%)

19th Aug 2026 | 1:43 PM

NSE : QLINE

Open Free Demat Account

QLine Biotech Performance

Price Movement

₹517.00

₹514.05

₹529.95

↘ Today's Low↗ Today's High

1 Year Performance

₹517.00

₹431.00

₹600.00

↘ 52 Week Low↗ 52 Week High

Markets Today

High₹529.95

Low₹514.05

Open at₹525.05

Prev Close₹524.05

Volumes35.60 K

Avg Price₹521.50

Lower Circuit₹419.25

Upper Circuit₹628.85

Historical Performance

3M High₹600.00

3M Low₹431.00

1 Yr High₹600.00

1 Yr Low₹431.00

3 Yr High₹600.00

3 Yr Low₹431.00

5 Yr High₹600.00

5 Yr Low₹431.00

Summary

As of 19-08-2026 14:22, Q-Line Biotech Ltd. share price today is ₹0, with a change of ₹-524.05 (-100.00%) from the previous close of ₹524.05. The stock opened at ₹525.05 and traded between ₹514.05 and ₹529.95, with a total traded volume of 35600 shares. The company has a market capitalization of ₹1234.4 Cr in the Healthcare sector. while its 52-week high and low are ₹600 and ₹431, respectively.

Q-Line Biotech Ltd. valuation metrics include a P/E ratio of 22.2, EPS of ₹34.79, and book value of ₹5.20. Profitability indicators show ROE of 22.63%.

Q-Line Biotech Ltd. technical indicators include Day RSI at 49.64, Day MFI at 68.46, Day ADX at 19.38. Additional indicators include Commodity Channel Index (CCI) at 19.4 and Williams %R at -47.61. Momentum indicators show Day MACD at 2.3, Day MACD Signal Line at 2.77, DayATR at 20.03. Rate of Change indicators for Q-Line Biotech Ltd. include ROC21 at -1.62.

Exponential moving averages include EMA5 at ₹532, EMA10 at ₹532.2, EMA12 at ₹532, EMA20 at ₹531, EMA26 at ₹529.7, EMA50 at ₹527.3. Simple moving averages include SMA5 at ₹532.5, SMA10 at ₹535.6, SMA20 at ₹524.5, SMA30 at ₹530.6, SMA50 at ₹533.3.

Support levels for QLine Biotech are placed at First Support ₹518.93, Second Support ₹508.72, Third Support ₹498.43. Resistance levels are seen at First Resistance ₹539.43, Second Resistance ₹549.72, Third Resistance ₹559.93. Q-Line Biotech Ltd. shareholding pattern shows promoter holding at 67.51%, FII holding at 1.67%, DII holding at 0%, public holding at 20.67%.

QLine Biotech Fundamentals

Market Cap

Above industry Median

1,234.40 Cr.

PE Ratio (TTM)

Below industry Median

22.20

Dividend Yield

Net Profit TTM

Net profit TTM

Net Profit Growth

Net profit TTM

PEG Ratio

ROE

52.8% incr over last year

22.63

Operating Revenue TTM

Operating Revenue Growth

Operating Revenue TTM

Book Value

Above industry Median

5.20

MFI

MFI is mid-range

68.46

RSI

RSI is mid-range

49.64

EPS (TTM)

34.79

Debt to Equity

0.92

Face Value

Operating Profit Margin Qtr.

28.22

Operating Profit Qtr.

Net Profit Qtr.

Operating Revenue Qtr.

PB Ratio

5.20

QLine Biotech Financials

Data not available for chart

Indicator
No Record Found

QLine Biotech Technicals

Q-Line Biotech Ltd. EMA & SMA

₹517.00

-15.80 (-2.97%)

↗ Bullish Moving Average

↘ Bearish Moving Average

Day EMA5 ₹532

Day EMA10 ₹532.2

Day EMA12 ₹532

Day EMA20 ₹531

Day EMA26 ₹529.7

Day EMA50 ₹527.3

QLine Biotech Support and Resistance

Resistance

First Resistance₹539.43

Second Resistance₹549.72

Third Resistance₹559.93

Support

First Support₹518.93

Second Support₹508.72

Third Support₹498.43

Technical Indicators

Day RSI49.64

Day MFI68.46

Day ADX19.38

Day Commodity Channel Index19.40

William-47.61

Day MACD2.30

Day MACD Signal Line2.77

Day ATR20.03

Day ROC125-

Day ROC21-1.62

QLine Biotech Shareholding Pattern

Held By
Promoter
FII
DII
Public

QLine Biotech Delivery And Volume

Period	Combined Delivery Volume	NSE+BSE Traded Volume Avg	Daily Avg Delivery Volume %
Day	23.2 K	32 K	72.50%
Week	31.84 K	41.52 K	76.69%
1 Month	56.55 K	83.73 K	67.54%
6 Month	78.23 K	97.74 K	80.04%

QLine Biotech SWOT Analysis

Strengths9

Weakness5

Opportunity0

Threats0

Benjamin Graham Value Screen

Consistent high performing stocks over Five Years

Rising Net Cash Flow and Cash from Operating activity

Relative Outperformance versus Industry over 1 Year

Annual Profit Growth higher than Sector Profit Growth

Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years

Company able to generate Net Cash - Improving Net Cash Flow for last 2 years

Companies with Zero Promoter Pledge

Stocks Outperforming their Industry Price Change in the Quarter

QLine Biotech Corporate Action

Ex-Date	Dividend Amount	Dividend Type	Record Date	Instrument Type
No Record Found

QLine Biotech Stock Comparison

Financials	Avience Biomedicals Ltd.	Gujarat Kidney and Super Speciality Ltd.	Invicta Diagnostic Ltd.	VijayPD Ceutical Ltd.	Galaxy Medicare Ltd.
Price (₹)	₹238.50	₹155.96	₹68.50	₹60	₹18.50
% Change	0.21%	1.63%	2.16%	0.00%	-0.54%
Revenue TTM (₹ Cr)	-	₹101.04	-	-	-
Net Profit TTM (₹ Cr)	-	₹15.83	-	-	-
PE TTM	10.90	75.40	18.70	23.40	8.70
1 Year Return	13.94	32.77	-14.12	71	-63.89
ROCE	31.13	8.56	13.56	14.18	-

Similar Stocks

No Data Available

FAQ's on QLINE

What is the Market Capitalization of Q-Line Biotech Ltd.?

Market capitalization (market cap) represents the total market value of a company's outstanding shares based on its current share price. As of 17 August 2026, the market cap for Q-Line Biotech Ltd. is approximately ₹ 1234.4 Cr.

What are the PE and PB ratios for Q-Line Biotech Ltd.?

Based on recent data, the Price-to-Earnings (PE) ratio for Q-Line Biotech Ltd. is 22.2, and the Price-to-Book (PB) ratio is 5.2.

What is the 52-Week High and Low for Q-Line Biotech Ltd.?

Over the past 52 weeks, the highest price reached by Q-Line Biotech Ltd. shares was ₹ 600, and the lowest price was ₹ 431.

Who are the major shareholders of Q-Line Biotech Ltd.?

Significant shareholdings in Q-Line Biotech Ltd. typically include entities such as:

Promoter
Public
Other Institutions
FII
Mutual Funds

(Note: Shareholding patterns can change; this represents major holders based on recent filings).

Who are the peers of Q-Line Biotech Ltd. in the Healthcare sector?

In the Healthcare sector, Q-Line Biotech Ltd. is often compared with other major players such as Molbio Diagnostics, Manipal Health Enterprises, Avience Biomedicals, Hannah Joseph Hospital and Modern Diagnostic Research for analysis and benchmarking.